INDEMNIFICATION AGREEMENTIndemnification Agreement • October 2nd, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of April 6, 2018 between Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), and John DeYoung (“Indemnitee”).
Allogene Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • October 2nd, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Allogene Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares of the Company’s common stock, par value $0.001 per share (“Stock, and such shares ”the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
INDEMNITY AGREEMENTIndemnity Agreement • October 2nd, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between ALLOGENE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
ASSET CONTRIBUTION AGREEMENT BY AND BETWEEN PFIZER INC. AND ALLOGENE THERAPEUTICS, INC. Dated as of April 2, 2018Asset Contribution Agreement • October 2nd, 2018 • Allogene Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Asset Contribution Agreement (this “Agreement”) is entered into as of April 2, 2018 (the “Effective Date”), by and between Pfizer Inc., a Delaware corporation (“Pfizer”), and Allogene Therapeutics, Inc., a Delaware corporation (“NewCo”).
